Matrigel uses in cell biology and for the identification of thymosin β4, a mediator of tissue regeneration

Applied Biological Chemistry

Table 3 Clinical trials with thymosin beta 4

Phase	Study	Number of patients
Completed trials
1	Dermal topical gel: safety study	15
1	Intravenous: safety study	60
2	Venous stasis ulcers: topical gel	72
2	Pressure ulcers: topical gel	71
2	Epidermolysis bullosa: topical gel	30
2	Neurotrophic keratitis: eye drops	9
2	Severe dry eye: eye drops	9
2	Moderate to severe dry eye: eye drops	72
2b/3	Moderate to severe dry eye: eye drops	317
3	Moderate to severe dry eye: eye drops	600
Ongoing trial
3	Neurotrophic keratitis: eye drops	46
Planned trials
2	Epidermolysis bullosa: dermal gel	15
3	Epidermolysis bullosa: dermal gel	150
3	Moderate to severe dry eye: eye drops	700

Outcomes all demonstrated safety and tolerability as well as efficacy trends and, in many cases, significant efficacy